TUMOR-NECROSIS-FACTOR (CACHECTIN) IN HUMAN VISCERAL LEISHMANIASIS

被引:100
|
作者
BARRALNETTO, M [1 ]
BADARO, R [1 ]
BARRAL, A [1 ]
ALMEIDA, RP [1 ]
SANTOS, SB [1 ]
BADARO, F [1 ]
PEDRALSAMPAIO, D [1 ]
CARVALHO, EM [1 ]
FALCOFF, E [1 ]
FALCOFF, R [1 ]
机构
[1] INST CURIE,INSERM,U196,F-75231 PARIS 05,FRANCE
来源
JOURNAL OF INFECTIOUS DISEASES | 1991年 / 163卷 / 04期
关键词
D O I
10.1093/infdis/163.4.853
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
High tumor necrosis factor-alpha (TNF-alpha) levels were present in the serum of 24 of 28 active visceral leishmaniasis (VL) patients (142.9 +/- 113.9 pg/ml, mean +/- SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infection, and 10 posttreatment VL cases). Serum TNF-alpha levels were also not elevated in 15 normal volunteers (11.3 +/- 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 +/- 10.8 pg/ml). Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNF-alpha production by these cells, and this effect was further potentiated by treatment with recombinant interferon-gamma. After effective treatment of VL patients, serum TNF-alpha levels dropped rapidly (129 +/- 112 vs. 9 +/- 13 pg/ml in 10 days), even before clinical parameters such as spleen size or parasitism, white blood cell count, or levels of hemoglobin returned to normal values. On the other hand, patients unresponsive to treatment remained with elevated levels (276 +/- 69 vs. 155 +/- 71 pg/ml in 10 days). Thus, serum TNF-alpha levels in VL patients are a good parameter to monitor in determining host response to therapy.
引用
收藏
页码:853 / 857
页数:5
相关论文
共 50 条
  • [31] CACHECTIN TUMOR-NECROSIS-FACTOR INDUCES LETHAL SHOCK AND STRESS HORMONE RESPONSES IN THE DOG
    TRACEY, KJ
    LOWRY, SF
    FAHEY, TJ
    ALBERT, JD
    FONG, Y
    HESSE, D
    BEUTLER, B
    MANOGUE, KR
    CALVANO, S
    WEI, H
    CERAMI, A
    SHIRES, GT
    SURGERY GYNECOLOGY & OBSTETRICS, 1987, 164 (05): : 415 - 422
  • [32] EFFECT OF TUMOR-NECROSIS-FACTOR CACHECTIN ON THE ACTIVITY OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR ON HUMAN SKIN FIBROBLASTS
    HARADA, K
    SHIMANO, H
    KAWAKAMI, M
    ISHIBASHI, S
    GOTODA, T
    MORI, N
    TAKAKU, F
    YAMADA, N
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 172 (03) : 1022 - 1027
  • [33] TUMOR-NECROSIS-FACTOR CACHECTIN(TNF)-INDUCED PULMONARY VASCULAR ENDOTHELIAL INJURY IN RABBITS
    GOLDBLUM, SE
    HENNIG, B
    JAY, M
    YONEDA, K
    MCCLAIN, CJ
    JOURNAL OF LEUKOCYTE BIOLOGY, 1987, 42 (05) : 551 - 551
  • [34] LACTATION STAGE-DEPENDENT CHANGES IN LEVELS OF TUMOR-NECROSIS-FACTOR CACHECTIN IN MILK
    REWINSKI, MJ
    YANG, TJ
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1994, 31 (04): : 170 - 173
  • [35] TUMOR-NECROSIS-FACTOR (CACHECTIN) IS AN ENDOGENOUS PYROGEN AND INDUCES PRODUCTION OF INTERLEUKIN-1
    DINARELLO, CA
    CANNON, JG
    WOLFF, SM
    BERNHEIM, HA
    BEUTLER, B
    CERAMI, A
    FIGARI, IS
    PALLADINO, MA
    OCONNOR, JV
    JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (06): : 1433 - 1450
  • [36] PROCESSING OF NEWLY SYNTHESIZED CACHECTIN TUMOR-NECROSIS-FACTOR IN ENDOTOXIN-STIMULATED MACROPHAGES
    JUE, DM
    SHERRY, B
    LUEDKE, C
    MANOGUE, KR
    CERAMI, A
    BIOCHEMISTRY, 1990, 29 (36) : 8371 - 8377
  • [37] CACHECTIN (TUMOR NECROSIS FACTOR) AND LYMPHOTOXIN
    BEUTLER, B
    ISI ATLAS OF SCIENCE-IMMUNOLOGY, 1988, 1 (02): : 101 - 105
  • [38] DETECTION OF TUMOR-NECROSIS-FACTOR CACHECTIN IN PLEURAL EFFUSION OF PATIENTS WITH LUNG-CANCER
    ISHII, Y
    UCHIYAMA, Y
    HASEGAWA, S
    KINOSHITA, T
    MITSUI, K
    KOJIMA, H
    FUJITA, T
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1990, 80 (03): : 350 - 353
  • [39] CACHECTIN TUMOR-NECROSIS-FACTOR REGULATES HEPATIC ACUTE PHASE GENE-EXPRESSION
    PERLMUTTER, DH
    DINARELLO, CA
    PUNSAL, P
    COLTEN, HR
    CLINICAL RESEARCH, 1986, 34 (02): : A650 - A650
  • [40] CACHECTIN TUMOR-NECROSIS-FACTOR PRIMES THE OXIDATIVE ACTIVITY OF NEUTROPHILS VIA RECEPTOR MOBILIZATION
    TENNENBERG, SD
    SOLOMKIN, JS
    CLINICAL RESEARCH, 1987, 35 (03): : A466 - A466